Treatment for HSV-2 Flare-Up in a 21-Year-Old Female
For a recurrent HSV-2 outbreak in this patient, start oral antiviral therapy immediately with one of the following regimens: acyclovir 400 mg three times daily for 5 days, acyclovir 800 mg twice daily for 5 days, valacyclovir 500 mg twice daily for 5 days, or famciclovir 125 mg twice daily for 5 days 1.
Episodic Treatment Approach
The key to effective episodic treatment is early initiation—ideally during the prodrome or within 1 day of lesion onset 1. Many patients benefit most when they can start therapy at the first sign of tingling, burning, or visible lesions. For this reason, provide the patient with a prescription to keep on hand so she can begin treatment immediately when symptoms appear 1.
Recommended Regimens (Choose One):
- Acyclovir 400 mg orally three times daily for 5 days, OR
- Acyclovir 200 mg orally five times daily for 5 days, OR
- Acyclovir 800 mg orally twice daily for 5 days, OR
- Famciclovir 125 mg orally twice daily for 5 days, OR
- Valacyclovir 500 mg orally twice daily for 5 days 1
Practical consideration: Valacyclovir and famciclovir offer simpler dosing schedules (twice daily vs. 3-5 times daily for acyclovir), which improves adherence, particularly important for a young adult 1. While all three medications are comparable in clinical outcomes, the convenience factor makes valacyclovir or famciclovir preferable for many patients 1.
Consider Suppressive Therapy
If this patient experiences frequent recurrences (≥6 outbreaks per year), strongly consider switching to daily suppressive therapy rather than episodic treatment 1, 2. Suppressive therapy reduces recurrence frequency by ≥75% and decreases asymptomatic viral shedding, thereby reducing transmission risk to sexual partners 1.
Suppressive Therapy Regimens (Choose One):
- Acyclovir 400 mg orally twice daily, OR
- Famciclovir 250 mg orally twice daily, OR
- Valacyclovir 500 mg orally once daily, OR
- Valacyclovir 1000 mg orally once daily 1
Important caveat: Valacyclovir 500 mg once daily is less effective in patients with very frequent recurrences (≥10 episodes per year); use higher doses or twice-daily regimens in these cases 1.
Safety data support acyclovir use for up to 6 years continuously, with valacyclovir and famciclovir documented for 1 year 1. After 1 year of suppressive therapy, reassess whether to continue based on recurrence patterns and the patient's psychological adjustment to the diagnosis 1.
Essential Counseling Points
Beyond antiviral therapy, comprehensive patient education is critical 1:
- Abstain from sexual activity when lesions or prodromal symptoms are present
- Asymptomatic viral shedding occurs frequently with HSV-2, meaning transmission can occur even without visible lesions 1
- Condom use during all sexual encounters should be encouraged, though it does not eliminate transmission risk entirely
- Inform sexual partners about the HSV-2 diagnosis
- Future pregnancy considerations: She must inform obstetric providers about HSV-2 status, as antiviral prophylaxis from 36 weeks gestation until delivery is recommended to reduce neonatal transmission risk 3
When to Escalate Care
Reserve IV acyclovir 5-10 mg/kg every 8 hours for severe disease requiring hospitalization, such as disseminated infection, hepatitis, pneumonitis, or CNS complications (meningitis, encephalitis) 1, 2. This is uncommon in immunocompetent patients but critical to recognize early 4.
Common Pitfalls to Avoid
- Topical acyclovir is substantially less effective than oral therapy and should not be used 1, 2
- Delaying treatment initiation significantly reduces efficacy—emphasize the importance of starting medication at the first sign of symptoms 1
- Failing to screen for other STIs at the time of diagnosis
- Inadequate counseling about transmission risk during asymptomatic periods, which is when most transmission occurs 1